Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer's Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma, Inc. (NASDAQ:SILO) is set to acquire an exclusive license for Alzheimer's disease therapeutic SPC-14 from Columbia University, showing promise in preclinical models for cognitive improvement and stress reduction. The global Alzheimer's disease therapeutics market is expected to exceed $30.8 billion by 2033. SPC-14 targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4, showing effectiveness in small animal studies.
April 10, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma acquires exclusive licensing for Alzheimer's therapeutic SPC-14, showing potential in preclinical models. Targets a rapidly growing market.
Acquiring exclusive licensing for a promising Alzheimer's therapeutic positions Silo Pharma favorably in a rapidly expanding market. The therapeutic's potential demonstrated in preclinical models and the significant market growth forecast for Alzheimer's disease treatments suggest a positive short-term impact on SILO's stock price. The confidence level reflects the early stage of the therapeutic's development and the uncertainties inherent in clinical trials and market acceptance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100